Mount Sinai DoctorsTreats Children
Accepting New Patients
Stanislav Lazarev, MD
Radiation Oncology
About Me
Stanislav (Stas) Lazarev, MD, is an Assistant Professor and Associate Program Director of Radiation Oncology Residency Program at Icahn School of Medicine at Mount Sinai in New York, NY. He provides patient care at both Mount Sinai Hospital and the New York Proton Center.
Dr. Lazarev's clinical practice is focused on the personalized treatment of pediatric malignancies, tumors of the central nervous system, including primary and metastatic brain tumors, metastatic spine tumors, and leptomeningeal disease, as well as treatment of primary liver and thoracic tumors with proton beam therapy.
His research interests include re-irradiation of brain tumors, proton craniospinal irradiation for leptomeningeal disease, stereotactic radiosurgery for intracranial metastases, and as well as proton radiation therapy for pediatric tumors. He is an active member of ASTRO, PTCOG, PROS/SIOP, PNOC, and Cure4Kids Initiative (The St. Jude International Outreach Program). Dr. Lazarev is a co-investigator in a number of prospective studies examining safety and efficacy of proton radiotherapy. He is institutional principal investigator of NRG Oncology BN012 clinical trial (NCT05438212) which is a randomized phase III trial of pre-operative compared to post-operative stereotactic radiosurgery in patients with resectable brain metastases. He is institutional sub-investigator of a randomized, open-label study of Optune (Tumor Treating Fields) concomitant with radiotherapy & temozolomide for the treatment of newly diagnosed glioblastoma (EF-32) (NCT04471844).
Apart from his clinical and research roles, Dr. Lazarev is actively engaged in mentoring and teaching trainees, particularly residents and medical students. He has been recognized for his dedication to education and was awarded the 2022 Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award.
Dr. Lazarev earned his BA in Biochemistry and Molecular Biology magna cum laude from the University of California--Berkeley. He received his medical degree from the University of Vermont College of Medicine, where he was inducted into the Alpha Omega Alpha National Honor Medical Society. He completed his medicine internship at Highland Hospital in Oakland, California, and his radiation oncology residency at the Icahn School of Medicine at Mount Sinai. During his residency, he served as the chief resident in the period 2018-2019. Dr. Lazarev has published numerous peer-reviewed papers covering a broad range of oncological topics and has presented his work at national conferences. He is an active expert contributor of TheMedNet.org (Neuro-Oncology and Pediatric Oncology sections). He is fluent in English, Russian, Spanish, Portuguese, and proficient in French.
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
About Me
Stanislav (Stas) Lazarev, MD, is an Assistant Professor and Associate Program Director of Radiation Oncology Residency Program at Icahn School of Medicine at Mount Sinai in New York, NY. He provides patient care at both Mount Sinai Hospital and the New York Proton Center.
Dr. Lazarev's clinical practice is focused on the personalized treatment of pediatric malignancies, tumors of the central nervous system, including primary and metastatic brain tumors, metastatic spine tumors, and leptomeningeal disease, as well as treatment of primary liver and thoracic tumors with proton beam therapy.
His research interests include re-irradiation of brain tumors, proton craniospinal irradiation for leptomeningeal disease, stereotactic radiosurgery for intracranial metastases, and as well as proton radiation therapy for pediatric tumors. He is an active member of ASTRO, PTCOG, PROS/SIOP, PNOC, and Cure4Kids Initiative (The St. Jude International Outreach Program). Dr. Lazarev is a co-investigator in a number of prospective studies examining safety and efficacy of proton radiotherapy. He is institutional principal investigator of NRG Oncology BN012 clinical trial (NCT05438212) which is a randomized phase III trial of pre-operative compared to post-operative stereotactic radiosurgery in patients with resectable brain metastases. He is institutional sub-investigator of a randomized, open-label study of Optune (Tumor Treating Fields) concomitant with radiotherapy & temozolomide for the treatment of newly diagnosed glioblastoma (EF-32) (NCT04471844).
Apart from his clinical and research roles, Dr. Lazarev is actively engaged in mentoring and teaching trainees, particularly residents and medical students. He has been recognized for his dedication to education and was awarded the 2022 Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award.
Dr. Lazarev earned his BA in Biochemistry and Molecular Biology magna cum laude from the University of California--Berkeley. He received his medical degree from the University of Vermont College of Medicine, where he was inducted into the Alpha Omega Alpha National Honor Medical Society. He completed his medicine internship at Highland Hospital in Oakland, California, and his radiation oncology residency at the Icahn School of Medicine at Mount Sinai. During his residency, he served as the chief resident in the period 2018-2019. Dr. Lazarev has published numerous peer-reviewed papers covering a broad range of oncological topics and has presented his work at national conferences. He is an active expert contributor of TheMedNet.org (Neuro-Oncology and Pediatric Oncology sections). He is fluent in English, Russian, Spanish, Portuguese, and proficient in French.
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
